Drug Combination Details
| General Information of the Combination (ID: C76612) | |||||
|---|---|---|---|---|---|
| Name | Magnolol NP Info | + | Azoles Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Candidosis
[ICD-11: 1F23]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | Candida albicans | Microorganism model | Candida albicans | |||
| Experimental
Result(s) |
Magnolol synergizes with azoles for targeting of C. albicans by inducing a higher intracellular content of antifungals, by tapping into the competitive effect of ABC transporter Cdr1p substrates, and enhancing the effect by targeting of the ergosterol biosynthesis pathway. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergistic activity of magnolol with azoles and its possible antifungal mechanism against Candida albicans. J Appl Microbiol. 2015 Apr;118(4):826-38. | |||
